# Vidofludimus Calcium for Primary Sclerosing Cholangitis

> **NCT03722576** · PHASE2 · COMPLETED · sponsor: **Elizabeth Carey** · enrollment: 18 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Vidofludimus calcium

## Key facts

- **NCT ID:** NCT03722576
- **Lead sponsor:** Elizabeth Carey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722576, "Vidofludimus Calcium for Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03722576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*